Hainan Poly Pharm (300630.SZ): Major violations have triggered mandatory (Delisted) status. From January 7, it will be subject to "Delisting Risk Warning."

Hainan Poly Pharm (300630.SZ) issued an announcement that the company is suspected of illegal information disclosure and has been investigated by the China Securities Regulatory Commission.

Zhitong FinanceJan 5 03:18 ET

December 10 A-share investment risk avoidance | Shenzhen SDG Service: Shareholder Silver Kun Company and Longxin Construction plan to collectively shareholding not exceeding 2%.

Hainan Poly Pharm: Currently under investigation by the Securities Regulatory Commission. There is a risk of being subjected to compulsory delisting due to major illegal activities involving stocks.

Gelonghui FinanceDec 9, 2024 09:20 ET

Hainan Poly Pharm (SZSE:300630) Adds CN¥615m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 77%

Simply Wall StDec 2, 2024 18:01 ET

Puli Pharmaceuticals: Third Quarter Report 2024 (after correction)

SZSINov 4, 2024 06:42 ET · Announcements

Puli Pharmaceuticals: Corrections to the 2024 Third Quarter Report

SZSINov 4, 2024 06:42 ET · Announcements

Hainan Poly Pharm (SZSE:300630) Is Making Moderate Use Of Debt

Simply Wall StNov 4, 2024 00:51 ET